Portfolio

Circadian Therapeutics is developing a portfolio of products to treat diseases related to treat circadian rhythm disorders.

We are rapidly moving CT-1500, our initial product for Non-24, towards NDA/MAA.

We are researching other pathways and validating efficacy of lead candidate drugs in non-human disease models, and will license these products as they become clinic-ready.

Overview of product development status